Dyspnea in palliative care: expanding the role of corticosteroids
- PMID: 22385025
- PMCID: PMC7001421
- DOI: 10.1089/jpm.2011.0260
Dyspnea in palliative care: expanding the role of corticosteroids
Abstract
Dyspnea is one of the most common symptoms in advanced cancer patients at the end of their life. It is often multifactorial with diverse malignant, nonmalignant, and cancer treatment related etiologies. Oxygen, opiates, and anxiolytics are commonly administered. Here a complex case of progressive dyspnea and its treatments in a patient with advanced pancreatic cancer is described, and its multiple potential contributing causes are identified and clinical responses evaluated. Literature review is conducted on pulmonary drug toxicity and tumor lymphangitic spread, and the role of corticosteroids in relieving dyspnea in the palliative care setting.
Conflict of interest statement
No conflicting financial interests exist.
Figures
Similar articles
-
Predictors of response to corticosteroids for dyspnea in advanced cancer patients: a preliminary multicenter prospective observational study.Support Care Cancer. 2017 Apr;25(4):1169-1181. doi: 10.1007/s00520-016-3507-5. Epub 2016 Nov 29. Support Care Cancer. 2017. PMID: 27900548
-
Promoting Primary Palliative Care in Severe Chronic Obstructive Pulmonary Disease: Symptom Management and Preparedness Planning.J Palliat Care. 2019 Apr;34(2):85-91. doi: 10.1177/0825859718819437. Epub 2018 Dec 26. J Palliat Care. 2019. PMID: 30587083
-
Effectiveness of Corticosteroid Monotherapy for Dyspnea Relief in Patients with Terminal Cancer.J Pain Palliat Care Pharmacother. 2017 Jun;31(2):148-153. doi: 10.1080/15360288.2017.1301618. Epub 2017 Mar 30. J Pain Palliat Care Pharmacother. 2017. PMID: 28358257
-
Corticosteroids in advanced cancer.Oncology (Williston Park). 2001 Feb;15(2):225-34; discussion 234-6. Oncology (Williston Park). 2001. PMID: 11252935 Review.
-
[Dyspnea in cancer: causes and symptomatic treatment].Ned Tijdschr Geneeskd. 1999 Nov 27;143(48):2421-4. Ned Tijdschr Geneeskd. 1999. PMID: 10608976 Review. Dutch.
Cited by
-
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.Cells. 2022 Feb 22;11(5):770. doi: 10.3390/cells11050770. Cells. 2022. PMID: 35269392 Free PMC article. Review.
-
Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults.Cochrane Database Syst Rev. 2019 Feb 20;2(2):CD012704. doi: 10.1002/14651858.CD012704.pub2. Cochrane Database Syst Rev. 2019. PMID: 30784058 Free PMC article.
-
Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.Cancers (Basel). 2020 Feb 27;12(3):546. doi: 10.3390/cancers12030546. Cancers (Basel). 2020. PMID: 32120803 Free PMC article. Review.
-
Do Patients Benefit from a Trial of Corticosteroids at the End of Life?Curr Treat Options Oncol. 2022 Jun;23(6):796-805. doi: 10.1007/s11864-022-00977-x. Epub 2022 Apr 1. Curr Treat Options Oncol. 2022. PMID: 35362799 Review.
-
[Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors].Zhongguo Fei Ai Za Zhi. 2019 Dec 20;22(12):786-793. doi: 10.3779/j.issn.1009-3419.2019.12.09. Zhongguo Fei Ai Za Zhi. 2019. PMID: 31874675 Free PMC article. Chinese.
References
-
- Thomas JR. von Gunten CF. Management of dyspnea. J Support Oncol. 2003;1:23–34. - PubMed
-
- Manning HL. Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med. 1995;333:1547–1553. - PubMed
-
- Reuben DB. Mor V. Dyspnea in terminally ill cancer patients. Chest. 1986;89:234–236. - PubMed
-
- Dudgeon DJ. Kristjanson L. Sloan JA. Lertzman M. Clement K. Dyspnea in cancer patients: Prevalence and associated factors. J Pain Symptom Manage. 2001;21:92–95. - PubMed
-
- Cachia E. Ahmedzai SH. Breathlessness in cancer patients. Eur J Cancer. 2008;44:1116–1123. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical